Aim immunotech receives ind clearance from the u.s. fda to advance its phase 2 study of ampligen® for the treatment of locally advanced pancreatic cancer

Data seen to date indicates that ampligen® (rintatolimod) could be a potential effective maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer

AIM Ratings Summary

AIM Quant Ranking